Peer-reviewed veterinary case report
Carboplatin safety and blood levels after IV or under-skin doses
By Iwano, Masataka et al.·Published in The Journal of veterinary medical science·2021·Veterinary Teaching Hospital, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serum concentration and safety of intravenous drip versus subcutaneous administration of carboplatin in dogs.
- Species:
- dog
Plain-English summary
A group of five dogs with cancer received treatment with carboplatin, a chemotherapy drug, either through an intravenous drip or by injection under the skin. Both methods were found to have similar safety profiles, with no major side effects observed, although some blood test changes were noted. The subcutaneous method took longer for the drug to reach its peak level in the blood but stayed in the system longer than the intravenous method. This study suggests that giving carboplatin under the skin could be a good option for dogs, especially when intravenous treatment is difficult.
People also search for: dog cancer treatment options · carboplatin for dogs · subcutaneous chemotherapy for dogs
Abstract
Carboplatin is used to treat certain cancers in dogs and cats and is routinely administered via intravenous drip (IVD). Subcutaneous (SC) administration has also been described. However, the toxicity, serum concentrations, and area under blood concentration-time curves (AUCs) of SC carboplatin are unknown. This study aimed to compare serum carboplatin concentrations in dogs after SC and IVD and to monitor any adverse events. In this crossover study, five dogs received SC or IV carboplatin (300 mg/m). After a minimum of 3 weeks, each dog received the other treatment. No gross skin toxicity or abnormal clinical signs were observed in any of the dogs. Blood test abnormalities were detected in most dogs. Decreased neutrophil and platelet counts, and increased C-reactive protein (CRP) levels were found. There was no significant difference in the neutropenia, thrombocytopenia, and CRP scores between the groups. Systemic toxicities of SC carboplatin were comparable to those of IVD carboplatin. The time to maximum carboplatin concentration after SC was longer than that after IVD (P<0.001). SC carboplatin remained in the serum longer than IVD carboplatin (P=0.008). The AUC of SC was less than that of IVD (P=0.002). The AUC and time taken to reach the maximum concentration of SC carboplatin were lower than those of IVD carboplatin. This study suggests that SC carboplatin may be an efficacious option for the treatment of tumors in dogs, particularly where IVD administration is challenging.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33716231/